vanzacaftor
Trade name: Alyftrek
Small moleculeapproved
Approved
Dec 20, 2024
Clinical trial activity
4 trials · 1 clinical orgs · 1 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Apr 26, 2023 (NCT05867147)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Cystic fibrosis transmembrane conductance regulatorPOSITIVE MODULATOR
Cystic fibrosis transmembrane conductance regulator positive modulator
CFTR modulator
Combination products
alyftrek
with tezacaftor, deutivacaftor
Also known as vanzacaftor, tezacaftor, and deutivacaftor
Approval history
- approvedDec 20, 2024
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)C[C@@H]2CCCNc3cccc(n3)S(=O)(=O)NC(=O)c3ccc(-n4ccc(OCCC5C6(CC6)C56CC6)n4)nc3N1C2- Mol. weight
- 617.78 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068396 ↗
- ChEMBLCHEMBL5314934 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06299696 | Phase 1 | Mar 26, 2024 | Vertex |
| NCT06299709 | Phase 1 | Mar 13, 2024 | Vertex |
| NCT05844449 | Phase 3 | Aug 11, 2023 | Vertex |
| NCT05867147 | Phase 1 | Apr 26, 2023 | Vertex |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vertex | For profit | 4 | 4 | 2 | 2023 |
1 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | NDA | Dec 20, 2024 |